Can Cirrhosis Be Reversed? The Stages and Process

Cirrhosis was long considered a one-way street, the final irreversible stage of chronic liver disease. That view has changed. Researchers now recognize cirrhosis as a dynamic process that can, under the right conditions, partially regress when the underlying cause of liver injury is removed or controlled. But “partially” is a word that does a lot of heavy lifting here, because the degree of reversal depends on how far the disease has progressed, what caused it, and whether certain structural changes in the liver have already become permanent.

How Cirrhosis Develops in Stages

Cirrhosis does not appear overnight. It develops after years of chronic inflammation that gradually replaces healthy liver tissue with scar tissue and abnormal regenerative nodules, eventually raising blood pressure in the portal vein system that feeds the liver.¹ The process typically moves through recognizable phases. In the earliest phase, fat accumulates in liver cells (steatosis). If inflammation sets in, the condition progresses to steatohepatitis, and repeated bouts of inflammation trigger the liver’s wound-healing response, which deposits collagen and other scar proteins. Over time, this fibrosis thickens and bridges between blood vessels, and if it continues, the architecture of the liver becomes distorted enough to qualify as cirrhosis.

Once cirrhosis is established, clinicians divide it into two broad categories. In compensated cirrhosis, the liver is scarred but still functional enough that the person has no obvious symptoms. In decompensated cirrhosis, the liver can no longer keep up: fluid collects in the abdomen (ascites), veins in the esophagus swell and bleed (variceal bleeding), or confusion develops from toxins the liver can no longer clear (hepatic encephalopathy). The jump from compensated to decompensated is a major turning point. Patients who develop more than one of these complications at the same time face a sharply higher mortality risk; at each stage, developing an additional complication roughly doubles the chance of death.²

The important shift in thinking is that movement between these stages is not strictly one-directional. Cirrhosis can progress from compensated to decompensated, but it can also regress from decompensated back to compensated, and from compensated cirrhosis back toward less severe fibrosis.³ This bidirectional nature is what makes the question of reversal so interesting and so complicated.

What the Liver Does to Undo Scar Tissue

The scar tissue in a fibrotic or cirrhotic liver is mostly collagen and other structural proteins collectively called the extracellular matrix. When the source of injury is removed, the liver has two main strategies for clearing that scar tissue. Both involve dealing with the cells that produced it in the first place: hepatic stellate cells. In a healthy liver, these cells are quiet. During chronic injury, they activate into a form that behaves like wound-repair cells, pumping out collagen. For fibrosis to reverse, those activated cells need to either die off or go back to sleep.

Research has confirmed both routes. The longer-established mechanism is apoptosis, where the activated stellate cells are cleared through programmed cell death. Rodent studies have shown that experimentally boosting this process accelerates the resolution of fibrosis.⁴ A second mechanism, discovered more recently, is reversion: activated stellate cells can return to a quiet state rather than dying. This deactivated state is not identical to their original condition, but it stops the cells from continuing to produce scar proteins.⁵

Once the stellate cells are cleared or deactivated, the liver needs to break down the collagen they left behind. This job falls to a family of enzymes called matrix metalloproteinases, or MMPs. These enzymes chew through collagen and other scar components. During active liver injury, their activity is held in check by inhibitor proteins (TIMPs), which is partly why scar tissue accumulates. When the injury stops, the balance shifts: MMP activity rises and TIMP activity drops, allowing the scar to be gradually degraded.⁶ The picture is not simple, though. Different MMPs play different roles at different stages of disease. Some MMP activity in early fibrosis can actually damage surrounding tissue and worsen the problem, while in later stages, the same enzymes help clear established scar.⁷

Does the Cause of Cirrhosis Affect Whether It Can Reverse?

Yes, and this is one of the most practical things to understand. The likelihood and degree of regression depend heavily on what caused the liver damage in the first place, because different causes respond differently to treatment.

Hepatitis B

Chronic hepatitis B is one of the clearest success stories for fibrosis regression. Long-term antiviral therapy with drugs like entecavir has been shown to reverse advanced fibrosis and even cirrhosis on liver biopsy. In one long-term study, all ten patients with advanced fibrosis or cirrhosis at baseline showed improvement in fibrosis scores after extended entecavir treatment, with some patients dropping from the highest cirrhosis score to near-normal levels.⁸ Viral suppression does not need to fully eliminate the virus; keeping it under control long enough allows the liver’s repair mechanisms to work. Current evidence supports treating all hepatitis B patients with advanced fibrosis or cirrhosis with antivirals, specifically because regression is achievable.⁹

Hepatitis C

The advent of direct-acting antiviral drugs transformed hepatitis C from a chronic, often progressive infection into a curable one. Curing the virus (achieving what’s called a sustained virologic response) removes the ongoing source of liver inflammation. Data from the earlier interferon treatment era showed that cirrhosis could reverse after viral eradication, but mainly in patients whose cirrhosis was still in its initial stages.¹⁰ More recent data from the direct-acting antiviral era indicates that fibrosis reversal continues to occur, and emerging evidence suggests that even cirrhosis reverses in some patients after the virus is cleared.¹¹

One complication: non-invasive tests like liver stiffness measurements often show rapid improvement after hepatitis C cure, but some of that early drop in stiffness reflects the resolution of inflammation rather than the slower process of actual scar breakdown.¹⁰ The fibrosis itself takes longer to dissolve, so test improvements in the first months after treatment can be somewhat misleading.

Alcohol-Related Liver Disease

For people whose cirrhosis is driven by heavy alcohol use, stopping drinking is the single most impactful intervention. In one study of patients with severe alcoholic cirrhosis who achieved abstinence, about two-thirds showed improvement in their liver function scores within three months.¹² Not everyone improves, however, and a small number of abstinent patients still deteriorate to the point of needing a transplant. The earlier in the disease course abstinence begins, the better the chances of meaningful recovery.

Fatty Liver Disease and Obesity

Metabolic dysfunction-associated steatotic liver disease (the updated name for what was long called nonalcoholic fatty liver disease) is now one of the most common causes of chronic liver disease worldwide. The scarring it causes can progress all the way to cirrhosis, with a 7- to 10-year liver-related mortality of roughly 12% to 25% once cirrhosis is established.¹³ Weight loss is the cornerstone of treatment, and effective, sustained weight loss can improve the liver’s fat content, resolve inflammation, and potentially reverse fibrosis.¹⁴ Bariatric surgery in particular has shown benefits in improving liver tissue and associated metabolic problems in selected patients.¹⁵ The challenge is that the degree of weight loss required is substantial, and maintaining it long-term is difficult for many people.

Autoimmune Hepatitis

Even in autoimmune liver disease, where the body’s immune system attacks the liver, fibrosis regression has been documented. In one study, patients who had cirrhosis or extensive fibrosis at diagnosis showed dramatic improvement on follow-up biopsy after responding to immunosuppressive treatment, with median fibrosis scores dropping from 3.3 to 0.8.¹⁶ These results reinforce the broader principle: remove or control the source of ongoing injury, and the liver has a remarkable capacity to heal.

What Does Not Reverse

The encouraging evidence on fibrosis regression comes with important caveats that are easy to overlook. The most significant is that even when scar tissue measurably decreases, the liver may not fully return to its original architecture. The vascular changes that develop in cirrhosis, where the normal network of tiny blood vessels becomes distorted, appear to persist even when fibrosis regresses. There is no strong evidence that the abnormal microcirculation in a cirrhotic liver completely normalizes.¹⁷ This matters because portal hypertension, the elevated pressure in the liver’s blood supply that drives many of cirrhosis’s worst complications, is partly maintained by these structural vascular changes, not just by the scar tissue itself.

Perhaps the most sobering limitation is cancer risk. Liver cancer (hepatocellular carcinoma) can develop in a cirrhotic liver, and that risk does not disappear when cirrhosis regresses. A case report documented a patient with hereditary hemochromatosis whose cirrhosis reversed with treatment, yet who still developed liver cancer years later.¹⁸ This is not an isolated observation. In hepatitis C patients who achieve viral cure and show documented cirrhosis regression, the debate continues over whether cancer surveillance should be maintained, because liver cancer can still emerge driven by prior carcinogenic effects of the virus and coexisting risk factors like alcohol or diabetes.¹⁹ The risk of further decompensation also lingers even after a patient successfully recompensates.²⁰ In short, a liver that has been cirrhotic is never quite the same as one that was never damaged, even if tests suggest significant improvement.

Tracking Regression Without Surgery

Historically, the only way to know whether fibrosis was improving was to take a tissue sample through liver biopsy, an invasive procedure with its own risks. That remains the gold standard for confirming the architecture of liver tissue, and some newer pathology frameworks now evaluate not just how much scar tissue is present but whether it looks like it is actively forming or actively dissolving, giving clinicians a more nuanced snapshot than traditional staging alone.²¹

Non-invasive alternatives have become far more common. Liver stiffness measurement (often done with a device called FibroScan) and blood-based scores like FIB-4 are widely used to estimate fibrosis severity without a biopsy. These tools are useful for screening and tracking trends, but they have real limitations. One study found that FibroScan correctly identified only about 46% of patients with biopsy-confirmed advanced fibrosis, while roughly 31% of patients who tested reassuringly normal on non-invasive tests actually had significant fibrosis on biopsy.²² FIB-4 scores are more useful when tracked over time. Longitudinal changes in FIB-4 have been strongly linked to the risk of progressing to cirrhosis and liver cancer,²³ and repeated measurements over several years can help identify people at high risk of severe liver disease, though the sensitivity still leaves room for improvement.²⁴

The practical takeaway is that if you or your doctor are monitoring fibrosis over time, a single test result is less meaningful than the trend across multiple tests. Improvement on non-invasive tests is encouraging, but it should not be taken as proof that cirrhosis has fully reversed, particularly in the early months after treating the underlying cause, when reduced inflammation can make the liver look better on scans before the scar tissue itself has changed much.

Emerging Approaches to Speeding Reversal

Most current strategies for reversing cirrhosis focus on removing the cause and letting the liver heal on its own. But researchers are exploring ways to actively assist that process. Stem cell therapy is one area of active investigation. Mesenchymal stem cells, typically derived from umbilical cord tissue or bone marrow, can migrate to damaged liver tissue and appear to help through several mechanisms: differentiating into liver-like cells, secreting growth factors that encourage surviving liver cells to divide, and dampening the inflammation that perpetuates damage.²⁵ Early trial results have been broadly positive in terms of safety and feasibility, though the field is still working out the best cell type, delivery method, and patient selection.²⁶

Another line of research focuses on the gut-liver axis. The liver receives blood directly from the intestines, so changes in gut bacteria can influence liver inflammation and scarring. In animal models of spontaneous fibrosis reversal, researchers have observed significant shifts in gut bacterial communities during the reversal process: populations of bacteria that produce butyrate (a short-chain fatty acid with anti-inflammatory properties) increased, and a beneficial species called Akkermansia became more abundant. These bacterial changes correlated with specific metabolic shifts, suggesting a tight link between gut microbial activity and the liver’s ability to break down scar tissue.²⁷ This work is still in its early stages, but it opens the door to the idea that manipulating gut bacteria, through diet, probiotics, or other interventions, might eventually help accelerate fibrosis regression.

When Reversal Is Not Enough and Transplant Becomes the Conversation

For some patients, removing the underlying cause of liver disease and waiting for the liver to heal is simply not an option because the damage is too advanced, decompensation is too severe, or the liver fails to improve despite treatment. Alcohol-related cirrhosis provides a clear illustration. While most patients who achieve abstinence see meaningful improvement in liver function within a few months, a small but real percentage do not recover. In one series, about 1.3% of abstinent patients with severe alcoholic cirrhosis ultimately required transplantation because their liver function continued to deteriorate despite quitting drinking.¹² Transplant evaluation in such cases is typically considered when liver function has not improved after a sustained period of abstinence, usually several months.

The decision is not purely medical. Transplant carries its own long-term risks, including the need for lifelong immunosuppressive medications and the possibility of disease recurrence in the new liver if the underlying cause is not fully controlled. For patients with cirrhosis from hepatitis C, transplant used to mean almost certain reinfection of the new liver, but direct-acting antivirals have largely solved that problem. For alcohol-related disease, the concern shifts to whether the patient can maintain abstinence long-term. These considerations are intensely personal and vary from one transplant program to another, but they underscore the reality that while reversal is possible in many cases, it is not guaranteed, and the safety net of transplant remains essential for those whose livers cannot recover on their own.

Pathology Beyond Fibrosis Scores

One development worth knowing about is a shift in how pathologists assess liver biopsies. Traditional staging systems assign a single number based on how much fibrosis is present, treating the scar tissue as a fixed quantity. But scar tissue in a liver undergoing regression looks different under the microscope than scar tissue in a liver that is getting worse. Thinning collagen strands, fragmented bands of fibrosis, and areas where hepatocytes are growing back into previously scarred zones are all signs that regression is underway. The Beijing classification system, developed specifically for the treatment era, introduced a separate assessment of whether fibrosis in a biopsy specimen appears predominantly progressive, predominantly regressive, or indeterminate. This quality-of-fibrosis assessment was found to correlate with post-treatment outcomes independently from the traditional fibrosis stage.²¹ In other words, two patients with the same fibrosis score on a traditional staging system might have very different trajectories if one has actively regressing scar tissue and the other does not. As treatment options improve and more patients live long enough for fibrosis to potentially reverse, this kind of qualitative assessment is becoming increasingly valuable for predicting who is actually getting better and who still needs close monitoring.